Latest News
Rezolute's ersodetug meets primary endpoint in Phase 3 upLIFT study of tumour hyperinsulinism
13 November 2026 - Rezolute, Inc. (NASDAQ: RZLT), a late-stage metabolic disease company focused on treating refractory hypoglycemia caused by hyperinsulinism, said preliminary results from a data evaluation show its open-label Phase 3 upLIFT study o...
Eisai launches subcutaneous Leqembi Pen in Japan for early Alzheimer's disease
13 November 2026 - Swedish research-based biopharma company BioArctic AB (STO: BIOA-B) on Friday said its Japanese partner Eisai Co Ltd (TYO: 4523) has launched Leqembi Pen, the subcutaneous formulation of lecanemab, in Japan for the treatment of ear...
Breakthrough T1D and Walgreens Foundation join forces to support the type 1 diabetes community
13 November 2026 - New York-based global type 1 diabetes (T1D) research and advocacy organisation Breakthrough T1D and the Walgreens Foundation announced on Thursday a new national partnership supporting Breakthrough T1D's mission and advancing ...
Sunnyside adds GLP-1 options to its medication program for Alcohol Use Disorder
13 November 2026 - Sunnyside, a US-based Alcohol Use Disorder (AUD) treatment and prevention company, announced on Thursday the launch of two new programs that pair semaglutide, a GLP-1 medication, with naltrexone, a medication FDA-approved for alcoh...
PAI Pharma acquires Nexus Pharmaceuticals
13 November 2026 - PAI Pharma (PAI), a portfolio company of Olympus Partners and a US-based developer, manufacturer, and marketer of oral liquid medicines and Ready-To-Use (RTU) sterile injectables, announced on Thursday the acquisition of Nexus Phar...